Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07366801CT.gov Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies | — | Recruiting | — | — | — |
NCT02638428CT.gov Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ruxolitinib (this asset) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P2/3 | B · 62 |
| Etoposide | Joanna Yi | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Methotrexate | Children's Oncology Group | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Romidepsin | Washington University School of Medicine | P3 | BB |
| Idarubicin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB |
+42 more in the Childhood Acute Myeloid Leukemia cohort
Other indications for Ruxolitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Myelofibrosis | — | P4 | BBB · 73 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BB · 70 |
| Graft Versus Host Disease | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ruxolitinib in Childhood Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ruxolitinib-childhood-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →